first reported that the chimeric gH redirected HSV, R-VG809, was engineered to retarget to the cancer cells by inserting the scFv-HER2 between AA 22 and 23 of gH and delete the AAs 6-38 of gD (Figure 2(C)). Here, ERBB2 is linked to cancer.